OTSUKA PHARM CO LTD
Big PharmaOTSUKA PHARM CO LTD is a major pharmaceutical company focused on Neurology, Cardiovascular, Dermatology. Key products include ABILIFY MAINTENA KIT.
FDA Novel Drug Designations
(2025)See 1 novel approval →
OTSUKA PHARM CO LTD at a Glance
- Strong track record with 100% execution quality across 5 trials
- Fast trial execution (20 months median completion)
OTSUKA PHARM CO LTD's Key Drugs
OTSUKA PHARM CO LTD's core commercial portfolio centers on ABILIFY MAINTENA KIT, REXULTI, ABILIFY ASIMTUFII, spanning Neurology and Cardiovascular — its most strategically important drugs approved in the last 15 years.
Schizophrenia
Major Depressive Disorder
Schizophrenia
Immunoglobulin A Nephropathy
Autosomal Dominant Polycystic Kidney Disease
OTSUKA PHARM CO LTD's Recent FDA Approvals
OTSUKA PHARM CO LTD secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
OTSUKA PHARM CO LTD's Therapeutic Areas
OTSUKA PHARM CO LTD's approved drugs and pipeline span 5 therapeutic areas, led by Neurology and Cardiovascular, across 0 biologic and 6 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
OTSUKA PHARM CO LTD's Top Competitors
OTSUKA PHARM CO LTD's closest competitors by therapeutic-area and drug-target overlap include Baxter, Bayer, and Pfizer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
OTSUKA PHARM CO LTD Pipeline Snapshot
OTSUKA PHARM CO LTD has 89 active clinical programs from ClinicalTrials.gov — 43 Phase 3, 19 Phase 2 and 27 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ABILIFY MAINTENA KIT leads revenue
- • 5 key drugs tracked
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 3/3 completed
- • Speed: 20 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (4)
Discontinued (1)
Company Info
- First Approval
- 1997-10-14
- Latest
- 2026-04-30
- Applications
- 16
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges